<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2015.66048</article-id><article-id pub-id-type="publisher-id">IJCM-56912</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Clinical Utility of Procalcitonin for Differentiating between Cryptogenic Organizing Pneumonia and Community-Acquired Pneumonia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>atoshi</surname><given-names>Takeda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nobuhiko</surname><given-names>Nagata</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hiroyuki</surname><given-names>Miyazaki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takanori</surname><given-names>Akagi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Taishi</surname><given-names>Harada</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Masaru</surname><given-names>Kodama</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shinichiro</surname><given-names>Ushijima</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takashi</surname><given-names>Aoyama</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kentaro</surname><given-names>Wakamatsu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Masaki</surname><given-names>Fujita</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kentaro</surname><given-names>Watanabe</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Respiratory Medicine, National Hospital Organization Omuta Hospital, Omuta, Japan</addr-line></aff><aff id="aff3"><addr-line>Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan</addr-line></aff><aff id="aff1"><addr-line>Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino, Japan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>nbnagata@fukuoka-u.ac.jp(NN)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>06</month><year>2015</year></pub-date><volume>06</volume><issue>06</issue><fpage>372</fpage><lpage>376</lpage><history><date date-type="received"><day>13</day>	<month>April</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>1</month>	<year>June</year>	</date><date date-type="accepted"><day>4</day>	<month>June</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Background: Differentiating cryptogenic organizing pneumonia (COP) from community-acquired pneumonia (CAP) can be difficult in some cases. Objective: To clarify the clinical utility of procalcitonin (PCT) levels for differentiating between COP and CAP. Methods: Blood PCT levels, leukocyte count, C-reactive protein concentration, number of segments involved on computed tomography (CT) images, and pneumonia severity assessment scale were retrospectively investigated from clinical charts and chest CT images of COP and CAP patients who we
   re admitted to our hospital from 2012 to 2014. The clinical characteristics of COP patients were compared to those of CAP patients for whom causative organisms were not detected. Results: There were 16 COP and 94 CAP patients for whom causative organisms were not detected. Blood PCT levels of all COP patients were less than 0.16 ng/dL, and significantly lower than those of CAP patients (p = 0.0004), while the number of involved segments was significantly higher than that of CAP patients (p = 0.0001). Blood PCT levels and the number of involved segments remained independently significant for differentiating between COP and CAP by multivariate analysis. Receiver operating characteristics curve analysis revealed that 7 was the best cut-off number for involved segments to differentiate between COP and CAP patients with low PCT levels (sensitivity 85.7%, specificity 94.7%). Conclusion: A combination of PCT levels and number of involved segments on CT images is useful for differentiation between COP and CAP. 
  
 
</p></abstract><kwd-group><kwd>Cryptogenic Organizing Pneumonia</kwd><kwd> Procalcitonin</kwd><kwd> Community-Acquired Pneumonia</kwd><kwd> Computed Tomography</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Patients with cryptogenic organizing pneumonia (COP) present with fever, infiltrative shadow on chest roentgenogram, and increased white blood cell count (WBC) or C-reactive protein (CRP) [<xref ref-type="bibr" rid="scirp.56912-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.56912-ref2">2</xref>] . Therefore, their clinical features resemble those of patients with community-acquired pneumonia (CAP), and many of these patients are, in fact, initially treated with antibiotics. A diagnosis of COP is made based on the presence of airspace filling by plugs of granulation tissue by transbronchial or surgical lung biopsy [<xref ref-type="bibr" rid="scirp.56912-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.56912-ref2">2</xref>] . However, obtaining biopsies can be difficult in some cases due to various reasons, such as severe hypoxemia, poor general condition, old age, or patient refusal.</p><p>Procalcitonin (PCT) is a biomarker specifically elevated in systemic bacterial infections [<xref ref-type="bibr" rid="scirp.56912-ref3">3</xref>] - [<xref ref-type="bibr" rid="scirp.56912-ref7">7</xref>] and has been shown to differentiate bacterial infections from other inflammatory conditions [<xref ref-type="bibr" rid="scirp.56912-ref8">8</xref>] . Therefore, PCT may have clinical utility in the differential diagnosis of COP and CAP. To our knowledge, there was only one report which examined PCT levels of patients with organizing pneumonia (OP). Kolditz et al. reported that PCT levels of OP patients were significantly lower than those of CAP patients, and all of OP patients showed bilateral infiltrates in chest imaging, in contrast to unilateral infiltrate of most CAP patients [<xref ref-type="bibr" rid="scirp.56912-ref9">9</xref>] .</p><p>This study aimed to clarify the clinical utility of PCT for differentiating between COP and CAP.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>Clinical charts and chest computed tomography (CT) images of all COP and CAP patients admitted to our hospital from April 2012 to December 2014 were retrospectively examined. Diagnoses of COP and CAP were reevaluated based on the consensus of two respiratory physicians. Diagnostic criteria of COP included the following: presence of intra-alveolar organization and absence of histologic findings inconsistent with those in COP (such as destruction of alveolar structure, necrosis, granuloma, or aggregates of neutrophils in TBLB); solitary or multifocal infiltrates found predominantly in the peribronchovascular or subpleural areas via CT; no microorganisms detected from respiratory specimens (including sputum, bronchial washing, or bronchoalveolar lavage fluid); and improvement of abnormal shadows with corticosteroid treatment. CAP was defined as an acute illness which occurred outside the hospital setting, and was associated with at least one of the following signs or symptoms: fever, new cough with or without sputum production, pleuritic chest pain, dyspnea, or altered breath sounds on auscultation, in addition to a chest radiograph showing an opacity compatible with the presence of acute pneumonia. Among CAP patients examined, those in whom a causative organism was not detected in sputum or by blood examination (pathogen unknown) were selected for comparison with COP patients. This is the patient population that presents difficulties in differentiating from COP patients. Blood PCT levels, leukocyte count, and CRP concentration examined at admission were investigated from clinical charts, and the number of segments involved on CT images taken within 24 hours of admission was also examined by two of the authors. The severity of pneumonia was assessed by the A-DROP scoring system, which is based on Japanese Respiratory Society guidelines. The ADROP scale is similar to the CURB-65 scale and provides a five-point score based on the following parameters: confusion, blood urea nitrogen &gt;21 mg/dL or the presence of dehydration, percutaneous oxygen desaturation (SpO<sub>2</sub> &lt; 90%), systolic blood pressure &lt;90 mmHg, and age &gt;70 years for men or &gt;75 years for women. Each criterion receives one point, resulting in a total score ranging from 0 to 5 points [<xref ref-type="bibr" rid="scirp.56912-ref10">10</xref>] . The system was also applied to COP patients. This study was approved by the Institutional Review Board of the Fukuoka University Chikushi Hospital.</p>Statistical Analysis<p>Data are presented as the median (interquartile range). The Mann-Whitney U test was used for comparisons between the two groups. Multivariate analysis was performed with logistic regression analysis. Receiver operating characteristic (ROC) curves were generated to determine the optimal cut-off for the number of involved segments in patients whose PCT levels were &lt;0.25 ng/mL. The optimal cut-off value was obtained from the best sensitivity/specificity ratio. Statistical analyses were performed with Excel Tokei 2010 (Social Survey Research Information, Co., Ltd., Tokyo, Japan). p &lt; 0.05 was considered statistically significant.</p></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Study Population</title><p>The clinical characteristics of patients are summarized in <xref ref-type="table" rid="table1">Table 1</xref>. The study population consisted of 16 (male/ female = 10/6) COP and 94 (male/female = 62/32) CAP patients. Median (interquartile range) age, PCT, WBC, CRP, number of involved segments, and ADROP score of COP, and CAP patients were 77.0 (69.0 - 78.0) years, and 74.5 (69.0 - 80.3) years; 0.05 (0.05 - 0.07) ng/mL, and 0.27 (0.11 - 1.59) ng/mL; 8000 (5700 - 8200)/mL, and 9700 (7500 - 12,800)/mL; 6.28 (1.34 - 8.97) mg/dL, and 9.83 (5.49 - 18.64) mg/dL; 8.0 (7.0 - 11.0), and 4.0 (2.0 - 5.0); and 1 (1 - 2), and 2 (1 - 2), respectively. Blood PCT levels of all COP patients were less than 0.16 ng/dL.</p></sec><sec id="s3_2"><title>3.2. Parameters Which Differentiate COP from CAP Patients</title><p>Of the parameters examined, PCT (p = 0.0004), WBC (p = 0.0093), and number of involved segments (p = 0.0001) were significantly different between COP and CAP patients (<xref ref-type="table" rid="table1">Table 1</xref>). Difference of CRP was marginal (p = 0.0567). Multivariate analysis revealed that PCT levels and the number of involved segments were independent factors that differed between COP and CAP patients (OR, 0.0000; 95% CI, 0.0000 - 0.1566; p = 0.0229 for PCT levels; OR, 2.1254; 95% CI, 1.2918 - 3.4969; p = 0.0030 for number of involved segments; <xref ref-type="table" rid="table2">Table 2</xref>). Multivariate analysis including CRP in addition to PCT levels, WBC, and the number of involved segments also showed that PCT levels and the number of involved segments were independent factors (odds ratio (OR), 0.0000; 95% confidence interval (CI), 0.0000 - 0.1926; p = 0.0264 for PCT levels; OR, 2.2030; 95% CI, 1.2699 - 3.8219; p = 0.0050 for number of involved segments).</p></sec><sec id="s3_3"><title>3.3. Cut-Off for Number of Involved Segments Which Differentiate COP from CAP Patients with Low PCT Levels</title><p>We determined the optimal cut-off for the number of involved segments which differentiates COP from CAP patients whose PCT levels were &lt;0.25 ng/mL using ROC curves. Seven was found to be the optimal cut-off (sensitivity, 85.7%; specificity, 94.7%; AUC, 0.945; <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Receiver operating characteristics curve of the number of involved segments for prediction of cryptogenic organizing pneumonia as compared with community-acquired pneumonia with blood procalcitonin levels &lt;0.25 ng/mL</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/2-2101105x6.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Baseline characteristics of patients with COP, and CAP</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >COP</th><th align="center" valign="middle" >CAP</th><th align="center" valign="middle" >p value COP vs CAP</th></tr></thead><tr><td align="center" valign="middle" >Number of patients</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Age, years</td><td align="center" valign="middle" >77.0 (69.0 - 78.0)</td><td align="center" valign="middle" >74.5 (69.0 - 80.3)</td><td align="center" valign="middle" >0.2285</td></tr><tr><td align="center" valign="middle" >Male/female</td><td align="center" valign="middle" >10/6</td><td align="center" valign="middle" >62/32</td><td align="center" valign="middle" >0.5369</td></tr><tr><td align="center" valign="middle" >PCT, ng/mL</td><td align="center" valign="middle" >0.05 (0.05 - 0.07)</td><td align="center" valign="middle" >0.27 (0.11 - 1.59)</td><td align="center" valign="middle" >0.0004</td></tr><tr><td align="center" valign="middle" >WBC, /μL</td><td align="center" valign="middle" >8000 (5700 - 8200)</td><td align="center" valign="middle" >9700 (7500 - 12800)</td><td align="center" valign="middle" >0.0093</td></tr><tr><td align="center" valign="middle" >CRP, mg/dL</td><td align="center" valign="middle" >6.28 (1.34 - 8.97)</td><td align="center" valign="middle" >9.83 (5.49 - 18.64)</td><td align="center" valign="middle" >0.0567</td></tr><tr><td align="center" valign="middle" >Number of involved segments</td><td align="center" valign="middle" >8.0 (7.0 - 11.0)</td><td align="center" valign="middle" >4.0 (2.0 - 5.0)</td><td align="center" valign="middle" >0.0001</td></tr><tr><td align="center" valign="middle" >ADROP score</td><td align="center" valign="middle" >1 (1 - 2)</td><td align="center" valign="middle" >2 (1 - 2)</td><td align="center" valign="middle" >0.2856</td></tr></tbody></table></table-wrap><p>COP: cryptogenic organizing pneumonia; CAP: community-acquired pneumonia; PCT: procalcitonin; WBC: white blood cell; CRP: C-reactive protein; ADROP: age, dehydration, respiration, orientation, and blood pressure. Data are presented as number or median (interquartile range).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Multivariate analysis of parameters which differentiate definite COP from CAP</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Odds ratio</th><th align="center" valign="middle" >95% Confidence interval</th><th align="center" valign="middle" >p value</th></tr></thead><tr><td align="center" valign="middle" >PCT, ng/mL</td><td align="center" valign="middle" >0.0000</td><td align="center" valign="middle" >0.0000 - 0.1566</td><td align="center" valign="middle" >0.0229</td></tr><tr><td align="center" valign="middle" >WBC, /μL</td><td align="center" valign="middle" >0.9998</td><td align="center" valign="middle" >0.9994 - 1.0002</td><td align="center" valign="middle" >0.3591</td></tr><tr><td align="center" valign="middle" >Number of involved segments</td><td align="center" valign="middle" >2.1254</td><td align="center" valign="middle" >1.2918 - 3.4969</td><td align="center" valign="middle" >0.0030</td></tr></tbody></table></table-wrap><p>COP: cryptogenic organizing pneumonia; CAP: community-acquired pneumonia; PCT: procalcitonin; WBC: white blood cell.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>PCT is considered the most useful laboratory marker for differentiating causes of fever, particularly in autoimmune, autoinflammatory, and malignant diseases [<xref ref-type="bibr" rid="scirp.56912-ref8">8</xref>] . Fever is the most prevalent symptoms noted in both CAP and COP patients [<xref ref-type="bibr" rid="scirp.56912-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.56912-ref2">2</xref>] . In fact, many COP patients are initially considered to have CAP and are treated with antibiotics. COP is a non-infectious, inflammatory condition, and patients with this condition are predicted to have low serum PCT levels. Though blood levels of other inflammatory markers such as WBC and CRP were also different between COP and CAP patients, multivariate analysis revealed that only PCT levels among inflammatory markers examined were independent factors that differed between COP and CAP patients.</p><p>Although a diagnosis of COP is confirmed by histological findings of polypoid granulation tissue in the airspace [<xref ref-type="bibr" rid="scirp.56912-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.56912-ref2">2</xref>] , it is sometimes difficult to perform biopsies for various reasons, such as poor general or respiratory status, old age, and patient refusal. In such situations, a decision must be made as to whether to administer corticosteroids. Our present findings apply to such situations, i.e., low serum PCT levels and &gt;7 involved segments (multilobar infiltrates) predict a favorable response to corticosteroids. Nonetheless, histological confirmation of COP remains of great importance.</p><p>Although PCT is useful for discriminating between infectious and non-infectious fever [<xref ref-type="bibr" rid="scirp.56912-ref8">8</xref>] , some CAP patients also exhibit low serum PCT levels. A cut-off of 7 involved segments by CT allowed for the discrimination of COP from CAP patients with low PCT levels and unknown causative pathogen with 85.7% sensitivity and 94.7% specificity. This suggests that the combination of low serum PCT levels and &gt;7 involved segments favors a diagnosis of COP over CAP. We chose CAP patients for whom the causative pathogen was unknown for comparison with COP patients because these are the patients that present diagnostic difficulties when differentiating CAP from COP.</p><p>Kolditz et al. conducted a similar investigation as the present study [<xref ref-type="bibr" rid="scirp.56912-ref9">9</xref>] , in which 15 histologically confirmed COP patients were compared with 15 CAP patients matched by age, sex, and disease severity. Their results were similar to ours, although the nature of CAP patients differed from that of the present study. We build on their findings by demonstrating that the number of involved segments on CT images can help discriminate COP patients from CAP patients who do not exhibit elevated serum PCT levels.</p><p>There are several limitations to this study. First, the number of COP patients was small. Second, the study was retrospective in nature. Although a prospective study that includes a large number of COP patients will be needed to confirm our results, the sporadic occurrence of COP may render a prospective study design difficult.</p></sec><sec id="s5"><title>5. Conclusion</title><p>COP patients exhibit significantly lower PCT levels and a significantly higher number of involved segments on CT images compared to CAP patients. A combination of PCT levels and number of involved segments on CT images is useful for differentiation between COP and CAP.</p></sec><sec id="s6"><title>Author Contributions</title><p>ST and NN contributed to the planning of the study, data analysis, and preparation, review, and submission of the manuscript. TA, TH, MK, SU, AS, and KW contributed to data collection, data analysis, and review and submission of the manuscript. MF and KW contributed to data analysis and review and submission of the manuscript.</p></sec><sec id="s7"><title>Conflict of Interest</title><p>None to report.</p></sec><sec id="s8"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.56912-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cordier, J.-F. (2006) Cryptogenic Organizing Pneumonia. European Respiratory Journal, 28, 422-446.http://dx.doi.org/10.1183/09031936.06.00013505</mixed-citation></ref><ref id="scirp.56912-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cottin, V. and Cordier, J.F. (2012) Cryptogenic Organizing Pneumonia. Seminars in Respiratory and Critical Care Medicine, 33, 462-475. http://dx.doi.org/10.1055/s-0032-1325157</mixed-citation></ref><ref id="scirp.56912-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Goros, C.A., Drosou, E., Bassaris, H.P. and Skoutelis, A. (2000) Proversus Anti-Inflammatory Cytokine Profile in Patients with Severe Sepsis: A Marker for Prognosis and Future Therapeutic Options. Journal of Infectious Diseases, 181, 176-180. http://dx.doi.org/10.1086/315214</mixed-citation></ref><ref id="scirp.56912-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Christ-Crain, M. and Mueller, B. (2005) Procalcitonin in Bacterial Infections—Hype, Hope, More or Less? Swiss Medical Weekly, 135, 451-460.</mixed-citation></ref><ref id="scirp.56912-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Christ-Crain, M. and Mueller, B. (2007) Biomarkers in Respiratory Tract Infections: Diagnostic Guides to Antibiotic Prescription, Prognostic Markers and Mediators. European Respiratory Journal, 30, 556-573. http://dx.doi.org/10.1183/09031936.00166106</mixed-citation></ref><ref id="scirp.56912-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Linscheid, P., Seboek, D., Zulewski, H., Keller, U. and Muller, B. (2005) Autocrine/Paracrine Role of Inflammation-Mediated Calcitonin Gene-Related Peptide and Adrenomedullin Expression in Human Adipose Tissue. Endocrinology, 146, 2699-2708. http://dx.doi.org/10.1210/en.2004-1424</mixed-citation></ref><ref id="scirp.56912-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Schuetz, P., Christ-Crain, M. and Mueller, B. (2009) Procalcitonin and Other Biomarkers to Improve Assessment and Antibiotic Stewardship in Infection—Hope for Hype? Swiss Medical Weekly, 139, 318-326.</mixed-citation></ref><ref id="scirp.56912-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Limper, M., de Kruif, M.D., Duits, A.J., Brandjes, D.P.M. and van Gorp, E.C.M. (2010) The Diagnostic Role of Procalcitonin and Other Biomarkers in Discriminating Infectious from Non-Infectious Fever. Journal of Infection, 60, 409-416. http://dx.doi.org/10.1016/j.jinf.2010.03.016</mixed-citation></ref><ref id="scirp.56912-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kolditz, M., Halank, M., Schulte-Hubbert, B. and Hoffken, G. (2012) Procalcitonin Improves the Differentiation between Infectious and Cryptogenic/Secondary Organizing Pneumonia. Journal of Infection, 64, 122-124.http://dx.doi.org/10.1016/j.jinf.2011.10.012</mixed-citation></ref><ref id="scirp.56912-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yanagihara, K., Kohno, S. and Matsushima, T. (2001) Japanese Guidelines for the Management of Community-Acquired Pneumonia. International Journal of Antimicrobial Agents, 18, S45-S48. http://dx.doi.org/10.1016/S0924-8579(01)00402-2</mixed-citation></ref></ref-list></back></article>